The drug is now the only available treatment for the condition that specifically targets inflammation.
A randomized phase 3 trial of the drug revealed that after 12 weeks of treatment, 65% of patients achieved clinical response and 24% achieved clinical remission. Other side effects from the condition including rectal bleeding and frequency of excrement improved after week three for many patients.
“Omvoh addresses key symptoms that matter most to patients and represents our patient-centric approach to treatment innovation,” said Patrik Jonsson, Lilly’s executive vice president and chief customer officer. “Omvoh’s approval is a significant moment for Lilly’s growing Immunology portfolio.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
